ArticleThoracic cancer2024

Prognostic factors and benefit populations of ovarian function suppression in premenopausal HR+/HER2+ early-stage breast cancer patients who received trastuzumab: Evidence from a real-world study with long-term follow-up.

Jie Ju et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.